AR087184A1 - Derivados de azaindol utiles para tratar infecciones por hiv y composiciones farmaceuticas que los contienen - Google Patents

Derivados de azaindol utiles para tratar infecciones por hiv y composiciones farmaceuticas que los contienen

Info

Publication number
AR087184A1
AR087184A1 ARP120102550A ARP120102550A AR087184A1 AR 087184 A1 AR087184 A1 AR 087184A1 AR P120102550 A ARP120102550 A AR P120102550A AR P120102550 A ARP120102550 A AR P120102550A AR 087184 A1 AR087184 A1 AR 087184A1
Authority
AR
Argentina
Prior art keywords
aryl
group
cycloalkyl
alkyl
heterocycle
Prior art date
Application number
ARP120102550A
Other languages
English (en)
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of AR087184A1 publication Critical patent/AR087184A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un compuesto que comprende la estructura de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde: L es un enlazador que se selecciona a partir del grupo que consiste en un enlace directo, un alquileno C1-6 de cadena ramificada o recta, -SO2-, -C(O)NH-, y un resto de formula (2), en donde los grupos R9 y R10, junto con el átomo de carbono con el que están enlazados, pueden unirse opcionalmente entre sí para formar un cicloalquilo C3-7; R1 se selecciona a partir del alquilo C1-6 o cicloalquilo C3-7; R2 se selecciona a partir del grupo que consiste en -CO2R9, -C(O)R15 y los restos del grupo de formulas (3); R3 se selecciona a partir del grupo que consiste en alquilo C1-6, -OR10, R10(R14)q, tetrahidrofuranilo, oxetanilo, furanilo, dioxolanilo, piranilo, dioxanilo, dioxinilo, -O-cicloalquilo C3-7, y -cicloalquilo C3-7-(R10); R4 se selecciona a partir del grupo que consiste en arilo C5-15, cicloalquilo C3-7, heterociclo C2-9, y heteroarilo C2-9, en donde el heterociclo y el heteroarilo cada uno comprenden de uno a tres heteroátomos seleccionados a partir del S, N u O, y en donde cada grupo R4 está opcionalmente sustituido por uno a cuatro sustituyentes seleccionados a partir del R11; R5, R6, y R7 se seleccionan independientemente a partir del -H, alquilo C1-6, alcoxilo C1-6, halógeno, nitrilo, cicloalquilo C3-7, -OR10-arilo C5-15, -OR10R14, -OR10-arilo C5-15, -OR10-arilo C5-14-(R11)m, -OR9, -R10(Y)-(R12)n, -OR10R17, -R10R17, -R17R15, -OR10(R14)q, -OR10(Y), -OR10R18, -OSO2R15, -R15, -arilo C5-15, -(Y), -(Y)-(R12)n, -C(O)-(Y), -C(O)R15, -R10-arilo C5-15, -R10R15, y -arilo C5-14-R12, en donde R5 y R6, junto con los átomos de carbono con los que están enlazados, pueden unirse opcionalmente entre sí para formar un anillo de cicloalquilo C4-7, de heterociclo C2-9, o de arilo C5-15, o de una manera alternativa, cuando L es un enlace, R6 y R7, junto con los átomos de carbono con los que están enlazados, pueden unirse opcionalmente entre sí para formar un anillo de heterociclo C3-7 o de cicloalquilo C3-7; R9 se selecciona independientemente a partir del -H y alquilo C1-6; R10 es alquilo C1-6; R11, R12, y R13 se seleccionan independientemente a partir del grupo que consiste en alquilo C1-6, alcoxilo C1-6, butoxi-carbonilo, oxo, -R10OR10, halógeno, -R15, -R10(R14)q, -OR10(R14)q, -SO2R10 -C(O)R10, -C(O)R15, y -R10R17; R14 es halógeno; R15 es -N(R16)2; R16 se selecciona independientemente a partir del grupo que consiste en -H, alquilo C1-6, hidroxilo, -SO2R10, -SO2N(R10)2, -C(O)NHR10, -C(O)R18, y -arilo C5-14-(R11); R17 es -OR9; R18 es -CO2R9; Y se selecciona independientemente a partir del heterociclo C2-9 o heteroarilo C2-9, en donde cada uno tiene de uno a tres heteroátomos seleccionados a partir del S, N u O; m es cero o un entero seleccionado a partir del 1, 2, 3, ó 4; n es cero o un entero seleccionado a partir del 1, 2, ó 3; p es cero o un entero seleccionado a partir del 1, 2, ó 3; y q es un entero seleccionado a partir del 1, 2, ó 3.
ARP120102550A 2011-07-15 2012-07-13 Derivados de azaindol utiles para tratar infecciones por hiv y composiciones farmaceuticas que los contienen AR087184A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161508197P 2011-07-15 2011-07-15

Publications (1)

Publication Number Publication Date
AR087184A1 true AR087184A1 (es) 2014-02-26

Family

ID=47519251

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102550A AR087184A1 (es) 2011-07-15 2012-07-13 Derivados de azaindol utiles para tratar infecciones por hiv y composiciones farmaceuticas que los contienen

Country Status (8)

Country Link
US (1) US8609653B2 (es)
EP (1) EP2731436B1 (es)
JP (1) JP6055468B2 (es)
AR (1) AR087184A1 (es)
ES (1) ES2624984T3 (es)
TW (1) TW201317237A (es)
UY (1) UY34201A (es)
WO (1) WO2013012649A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2817896A1 (en) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
EP2781519B1 (en) * 2011-11-15 2019-10-30 ST Pharm Co., Ltd. Novel antiviral pyrrolopyridine derivative and a production method for same
JP6129962B2 (ja) * 2012-07-12 2017-05-17 ヴィーブ ヘルスケア ユーケー リミテッド 化合物及びｈｉｖを治療するための方法
TW201441197A (zh) 2013-01-31 2014-11-01 Shionogi & Co Ｈｉｖ複製抑制劑
EP2821082A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use
EP3105236B1 (en) 2014-02-12 2017-10-18 ViiV Healthcare UK (No.5) Limited Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126743A1 (en) 2014-02-18 2015-08-27 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126758A1 (en) 2014-02-18 2015-08-27 Bristol-Myers Squibb Company Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
CN103864661A (zh) * 2014-04-01 2014-06-18 湖南华腾制药有限公司 一种2-氨基-3-氰基吡咯衍生物的合成工艺
WO2015174511A1 (ja) 2014-05-16 2015-11-19 塩野義製薬株式会社 Ｈｉｖ複製阻害作用を有する３環性複素環誘導体
KR101592370B1 (ko) * 2014-06-09 2016-02-11 한국화학연구원 신규한 피롤로피리딘 유도체 및 이의 hiv 저해제로서의 용도
RS57108B1 (sr) * 2014-07-08 2018-06-29 Viiv Healthcare Uk Ltd Derivati izoindolina za upotrebu u lečenju virusne infekcije
ES2703352T3 (es) 2014-07-22 2019-03-08 Viiv Healthcare Uk Ltd Derivados de isoindolina útiles como agentes antivirales
WO2016194806A1 (ja) 2015-05-29 2016-12-08 塩野義製薬株式会社 Ｈｉｖ複製阻害作用を有する含窒素３環性誘導体
US20180170903A1 (en) * 2015-07-06 2018-06-21 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
CA2991268A1 (en) 2015-07-08 2017-01-12 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
SG10201912699RA (en) * 2015-07-20 2020-02-27 Genzyme Corp Colony stimulating factor-1 receptor (csf-1r) inhibitors
US20190284136A1 (en) 2016-07-25 2019-09-19 Viiv Healthcare Uk Limited Indoline derivatives
CN110461837B (zh) * 2017-03-24 2022-06-17 St制药株式会社 新型吡咯并吡啶衍生物、其制备方法及用途
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
KR20220023187A (ko) * 2020-08-20 2022-03-02 에스티팜 주식회사 피롤로피리딘 유도체 및 이들의 용도
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤
CA3207714A1 (en) * 2021-01-11 2022-07-14 St Pharm Co., Ltd. Pyrrolopyridine derivative preparation method
CN113173884B (zh) * 2021-05-06 2023-08-15 陕西师范大学 二氯二茂钛催化汉斯酯1,4-二氢吡啶类化合物合成吡啶及其衍生物的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JP2003503386A (ja) * 1999-06-25 2003-01-28 メルク エンド カムパニー インコーポレーテッド １−（芳香族またはヘテロ芳香族置換）−３−（ヘテロ芳香族置換）−１，３−プロパンジオン類およびそれの使用
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
KR20030093248A (ko) 2001-03-19 2003-12-06 오노 야꾸힝 고교 가부시키가이샤 트리아자스피로[5.5]운데칸 유도체를 유효성분으로서함유하는 약제
EP1786813A2 (en) 2004-09-03 2007-05-23 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
BRPI0819328A8 (pt) * 2007-11-15 2016-02-10 Boehringer Ingelheim Int Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos
JP5269087B2 (ja) * 2007-11-16 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルス複製のインヒビター
EP2220046B1 (en) 2007-11-16 2014-06-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
EP2640705A2 (en) * 2010-11-15 2013-09-25 Katholieke Universiteit Leuven Novel antiviral compounds

Also Published As

Publication number Publication date
JP2014522858A (ja) 2014-09-08
US8609653B2 (en) 2013-12-17
EP2731436A1 (en) 2014-05-21
EP2731436A4 (en) 2015-03-11
EP2731436B1 (en) 2017-03-08
TW201317237A (zh) 2013-05-01
UY34201A (es) 2013-02-28
US20130018049A1 (en) 2013-01-17
JP6055468B2 (ja) 2016-12-27
ES2624984T3 (es) 2017-07-18
WO2013012649A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
AR087184A1 (es) Derivados de azaindol utiles para tratar infecciones por hiv y composiciones farmaceuticas que los contienen
AR081649A1 (es) Compuestos heteroarilo nitrogenados
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR085039A1 (es) DERIVADOS DE PURINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA PREPARACION DE MEDICAMENTOS PARA TRATAR ENFERMEDADES MODULADAS POR LA INHIBICION DE LA PI3K DE CLASE I Y/O mTOR
AR090121A1 (es) Compuestos de oxazolidin-2-ona y usos de los mismos
ES2556350T3 (es) Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
PE20160501A1 (es) Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih
AR082633A1 (es) Analogos de tetraciclina
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
AR085893A1 (es) Pirrolopirazina-amidas de piperidina espirociclica como moduladores de los canales ionicos
AR085549A1 (es) DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA
ES2626555T3 (es) Pyridone amides como moduladores de canales de sodio
AR094262A1 (es) Compuestos antivirales para el tratamiento de la hepatitis c
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR087792A1 (es) Compuestos heterociclicos tetraciclicos y metodos para el uso de los mismos en el tratamiento de enfermedades virales
AR091271A1 (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa
AR048607A1 (es) Derivados (poli)aminoalquilaminoacetamida de la epipodofilotoxina, proceso de preparacion de los mismos y sus aplicaciones terapeuticas como agentes anticancerosos
ES2640911T3 (es) Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus
AR088000A1 (es) Derivados de pirazolquinolinona, su preparacion y su uso terapeutico
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR078609A1 (es) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros.
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales

Legal Events

Date Code Title Description
FA Abandonment or withdrawal